Skip to main content
Equibles
ORIC logo

ORIC · Oric Pharmaceuticals, Inc. · Metrics

Track ORIC — free

Use ORIC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ORIC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.91 +1.19 (+9.36%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.32B
Shares
103.65M
Volume · Oct 20 2.02M Avg daily vol (3M) 1.49M

ORIC metrics

67 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$13.78
Market cap
$1.32B

Price action

20 metrics
Price change (1W)
+7.7%
Price change (30D)
+0.4%
Price change (3M)
+22.1%
Price change (6M)
+16.8%
Price change (YTD)
+55.5%
Price change (1Y)
-0.5%
Trailing year
Price change (5Y)
-14.9%
52-week high
$14.65
52-week low
$7.48
Change from 52-week high
-13.2%
Change from 52-week low
+70.2%
Annualized volatility
83.1%
Annualized volatility (3M)
76.8%
Beta
1.4
RSI (14D)
52.8
Price vs SMA 50
-1.8%
Price vs SMA 200
+15.1%
Avg volume (3M)
1.47M
Relative volume
0.8
Average dollar volume
$18.57M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
103.65M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.4
reciprocal yield 29.8%
FCF yield
-8.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-11.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2022-03-21

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$156.14M
Net income (TTM)
−$140.35M
Trailing 12 months
Diluted EPS (TTM)
$-1.30
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.50
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.35
Operating cash flow per diluted share (TTM)
$-1.07
Free cash flow per diluted share (TTM)
$-1.08
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$1.18
Stock compensation per diluted share (TTM)
$0.25
Book value per share
$3.90

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+38.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-36.8%
Return on assets
-34.7%
Debt / equity
0.0
Current ratio
13.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$112.26M
Quick ratio
13.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$37.48M
Latest balance sheet
Cash & equivalents
$37.48M
Total assets
$404.69M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$111.64M
Capital expenditures (TTM)
$620,000
R&D (TTM)
$122.36M
SG&A (TTM)
—
Stock compensation (TTM)
$25.90M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
180
13F filer change QoQ
-2
Institutional ownership
119.7%
Conviction holders (share of 13F filers)
4.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-1.1%
Holder tenure
12.0
Price vs estimated holder cost
+8.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.9%

Short interest

3 metrics
Short interest
15.7%
Latest settlement · 9.9 days to cover
Days to cover
9.9d
Short-squeeze score
97 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.49M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1796280 CUSIP 68622P109 13F (30d) 11 filings 11 filers Visit website Investor relations